The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

Share Price Information for polarean (POLX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.325
Bid: 1.30
Ask: 1.35
Change: -0.125 (-8.62%)
Spread: 0.05 (3.846%)
Open: 1.45
High: 1.40
Low: 1.275
Prev. Close: 1.45
POLX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New System Order

12 Oct 2020 07:00

RNS Number : 7062B
Polarean Imaging PLC
12 October 2020
 

Polarean Imaging Plc 

("Polarean" or the "Company")

 

New System Order

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces the Company has received its latest research unit order for a 9820 Xenon Polariser system from the University of Texas MD Anderson Cancer Center ("MD Anderson Cancer Center").

 

MD Anderson Cancer Center is a major cancer research and teaching hospital. This new unit will initiate their research programme using hyperpolarised noble gas imaging in oncology, including assessing lung function as consequence of chemotherapy and radiation therapies, and providing guidance for improved radiation treatment planning, among other topics.

 

 Richard Hullihen, CEO of Polarean, said: "We are excited to begin our relationship with MD Anderson Cancer Center who have pioneered such a breadth of oncology applications for medical imaging for this patient population, and welcome them to the group of our users researching the use of hyperpolarised 129 Xe in pulmonary function."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Jonathan Allis, Chairman

 

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

David Hignell / Soltan Tagiev (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

 

 

About Polarean (www.polarean.com)

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

 

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

 

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

 

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBGBDGRGBDGGG
Date   Source Headline
1st Dec 202011:05 amRNSSecond Price Monitoring Extn
1st Dec 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:00 amRNSTotal Voting Rights
23rd Oct 20204:41 pmRNSSecond Price Monitoring Extn
23rd Oct 20204:35 pmRNSPrice Monitoring Extension
23rd Oct 20202:05 pmRNSSecond Price Monitoring Extn
23rd Oct 20202:00 pmRNSPrice Monitoring Extension
20th Oct 20207:00 amRNSExercise of warrants
14th Oct 202011:00 amRNSPrice Monitoring Extension
12th Oct 20204:40 pmRNSSecond Price Monitoring Extn
12th Oct 20204:35 pmRNSPrice Monitoring Extension
12th Oct 20207:00 amRNSNew System Order
8th Oct 20205:05 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSNDA Submission
30th Sep 20207:00 amRNSHalf-year Report
18th Sep 20207:00 amRNSNew System Installation
30th Jul 20207:00 amRNSScientific presentations on hyperpolarized Xenon
13th Jul 20202:23 pmRNSResult of AGM
18th Jun 20207:00 amRNSFinal Results
1st Jun 20207:00 amRNSAppointment of Non-Executive Director
1st Jun 20207:00 amRNSExercise of Warrants
11th May 202011:05 amRNSSecond Price Monitoring Extn
11th May 202011:00 amRNSPrice Monitoring Extension
30th Apr 20206:30 pmRNSTotal Voting Rights
2nd Apr 20205:06 pmRNSHolding(s) in Company
2nd Apr 20202:12 pmRNSHolding(s) in Company
1st Apr 20203:32 pmRNSResult of General Meeting & Fundraise Completion
31st Mar 20207:00 amRNSTotal Voting Rights
25th Mar 20207:00 amRNSGeneral Meeting: Change of Venue
13th Mar 202012:51 pmRNSConditional Fundraise to raise £8.4 million
12th Mar 20204:41 pmRNSSecond Price Monitoring Extn
12th Mar 20204:36 pmRNSPrice Monitoring Extension
2nd Mar 20207:00 amRNSExercise of Warrants
3rd Feb 20207:00 amRNSDirectorate Change
29th Jan 20207:00 amRNSPositive pivotal Phase III Clinical Trials results
22nd Jan 20204:03 pmRNSDirector Dealing
13th Jan 20207:00 amRNSHolding(s) in Company
2nd Jan 20204:50 pmRNSDirector dealing
24th Dec 20197:00 amRNSNew System Delivery and Installation
12th Nov 20197:00 amRNSNew System Delivery and Installation
8th Nov 20197:00 amRNSGrant of options
7th Nov 20197:00 amRNSCompletion of patient enrolment & PDMR appointment
11th Oct 20194:17 pmRNSDirector dealing
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
9th Oct 20197:00 amRNSHolding(s) in Company
3rd Oct 20197:00 amRNSPolarean notes statement from Amphion Innovations
25th Sep 20197:00 amRNSPolarean notes statement from Amphion Innovations
24th Sep 20197:00 amRNSHalf-year Report
10th Sep 20195:15 pmRNSPolarean notes statement from Amphion Innovations
10th Sep 20197:00 amRNSNew System Installation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.